iBio helps clients develop and manufacture biotherapeutics from the early stages of product selection through regulatory approval and commercial launch. With its proprietary technology platform, iBio uses plants as the bioreactor, which yields significant time and value advantages over traditional approaches. iBio will present a real case study on the process and collaboration necessary to produce a bio-better rituximab for countries where access to these drugs is limited. The presentation will show the uses of plant transient expression and Plant-made Pharmaceuticals as a recognized method of developing therapeutics, and how this accelerates the ability of developing countries, where budgets can be extremely tight, to quickly be up and running for targeted therapies. By bringing its technology to places where certain therapies or vaccines are unaffordable or nonexistent, iBio is part of life-saving projects.